Author information
1Gastroenterology department, high specialty medical unit (UMAE) No. 25, Northeast National Medical Center, IMSS, Monterrey, Nuevo León, P.C. 64320, Mexic.
2Gastroenterology department, high specialty medical unit (UMAE) No. 25, Northeast National Medical Center, IMSS, Monterrey, Nuevo León, P.C. 64320, Mexic. Electronic address: almakuljacha@gmail.com.
3Gastroenterology Department, Zone General Hospital No. 33, IMSS, Monterrey, Nuevo León, P.C. 64010, Mexic.
4Gastroenterology Department, Zone General Hospital No. 17, IMSS, Monterrey, Nuevo León, P.C. 64420, Mexic.
Abstract
Introduction and objectives: Although the Psychometric Hepatic Encephalopathy Score (PHES) remains the gold standard in diagnosing minimal hepatic encephalopathy (MHE), its complexity limits its application in clinical practice. While more convenient tests, such as the Stroop test, Quickstroop, and the 1-min animal naming test (ANT-1), have emerged, they haven't been validated in our setting. Our objective was to validate these tests in our population.
Patients and methods: This multicenter, observational, descriptive, and cross-sectional study was conducted in three hospitals in northeastern Mexico. MHE was defined as a PHES <-4. We included patients with cirrhosis aged >15 years without a history of overt hepatic encephalopathy. Data regarding sex, age, education, Child-Pugh/MELD-Na scores, etiology of cirrhosis, diabetes, hypertension, obesity, ascites, and clinically significant portal hypertension was collected. Fisher's exact test, Mann-Whitney U test, and receiver operating characteristic (ROC) curves were used for statistical analysis.
Results: Of the 121 patients included, 35.5 % were diagnosed with MHE. The presence of MHE was significantly associated with education level, years of study, and scores in the Stroop test, Quickstroop, and ANT-1. The AUROC curves were 77.9 %, 74.6 %, and 72.7 % for the Stroop test, Quickstroop, and ANT-1, respectively. The resulting cut-off points were 218.398 (sensitivity: 74 %; specificity: 74 %), 40.535 (sensitivity: 77 %; specificity: 68 %), and <16 animals (sensitivity: 58 %; specificity: 79 %), respectively.
Conclusions: These tests are valid diagnostic tools for detecting MHE in our population. Their simpler use and applicability could increase the early diagnosis of MHE and prompt primary prophylaxis initiation for overt hepatic encephalopathy.